FDA committee recommends GSK shingles vaccine

07:46 14/09/2017
StockMarketWire.com - GlaxoSmithKline has announced that the US Food and Drug Administration's vaccines and related biological products advisory committee has voted unanimously that the data support the efficacy and safety of Shingrix for the prevention of herpes zoster (shingles) in adults aged 50 and over.

FDA advisory committees provide non-binding recommendations for consideration by the FDA, with the final decision on approval made by the FDA.

GSK senior vice-president and head of vaccines R&D, Dr. Emmanuel Hanon, said: "Shingles is a painful and potentially serious condition.

"The risk of developing shingles increases with age and it is estimated that up to one in three people in the United States will develop shingles.

"Today's vote brings us one step closer to approval of Shingrix, which is specifically designed to overcome age-related weakening of the immune system."



Story provided by StockMarketWire.com

Forex

Commodities

What the Papers Say

telegraph financial times daily mail daily express independent times
22:25 Milo Yiannopoulos to hold rally...
source: The Telegraph
22:09 Stratford acid attack: six people injured...
source: The Telegraph
22:09 Stratford acid attack: six people injured...
source: The Telegraph
22:00 Ted Hughes, the 'brilliant, rugged...
source: The Telegraph
22:00 Government urged to do more to help foster...
source: The Telegraph
22:00 ‘When will this nightmare...
source: The Telegraph
21:53 Stratford acid attack: six people injured...
source: The Telegraph
21:24 London Mayor Sadiq Khan could be in breach...
source: The Telegraph
21:13 Prince Harry lets five-year-old fan take...
source: The Telegraph
21:00 Ede & Ravenscroft accused of driving up...
source: The Telegraph
[more ...]